12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO, CA
Investor Presentation
Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Appoints Three New Members to its Board of Directors
Amended material disclosure
2026 Annual Meeting Results: Directors Elected and Compensation Approved
Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment.
Q2
Q1
FY 2025
Q3
FY 2024
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence